Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
"We are excited to open Marker's new in-house cGMP manufacturing facility and potentially bring our therapies to the affected patient communities," said
The Company employed modular processes to build its cGMP manufacturing facility at its 48,500 square foot location. Currently, about a third of the square footage is being utilized and is dedicated to support the Company's Phase 2 AML trial, which is expected to enroll 160 patients. Additional clean rooms may be added using the cost-effective and scalable modular processes for the manufacturing of other MultiTAA-specific T cell products in future clinical trials.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the potential commercialization of our current and future product candidates; our manufacturing processes and the cost thereof; and our ability to use our cGMP manufacturing facility to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other
View original content to download multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-announces-opening-of-new-cgmp-manufacturing-facility-301343458.html
Investors: Solebury Trout, Xuan Yang, (646) 378-2975, firstname.lastname@example.org, Media: Solebury Trout, Amy Bonanno, (914) 450-0349, email@example.com